drugset / Trial / NCT01606735

Efficacy and Safety of IBI-10090 in Ocular Surgery Patients

NCT01606735 ↗

Phase 2 Completed 172 enrolled ICON Bioscience Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will test the efficacy and safety of IBI-10090 in the treatment of ocular inflammation after ocular surgery.

Timeline

Start
2012-04
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule — —

Indications

No indication recorded.